ANXA3 and breast cancer: However, in SB2−/−;PyMT tumors, a high levels of IFN-γ, which activates the antitumor immune response [32], and a low levels of Anxa3, which controls cancer cell invasion and lung metastasis [33], do not support SerpinB2 deficiency causing a delay in PyMT-induced mammary tumor progression.